Skip to main content

Lazertinib Dosage

Medically reviewed by Drugs.com. Last updated on Oct 1, 2024.

Applies to the following strengths: 80 mg; 240 mg

Usual Adult Dose for Non-Small Cell Lung Cancer

240 mg orally once a day administered in combination with amivantamab

Duration of therapy: Until disease progression or unacceptable toxicity

Comments:


Use: For the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an US FDA-approved test

Renal Dose Adjustments

Mild and Moderate Renal Dysfunction (Estimated GFR [eGFR] 30 to 89 mL/min) : No adjustment recommended
Severe Renal Dysfunction and End Stage Renal Disease (eGFR less than 30 mL/min): Data not available

Liver Dose Adjustments

Mild and Moderate Liver Dysfunction: No adjustment recommended
Sever Liver Dysfunction: Data not available

Dose Adjustments

Recommended Dose Reductions for Adverse Reactions:


Venous Thromboembolic Events (VTE)


Interstitial Lung Disease (ILD) or Pneumonitis

Dermatologic Adverse Reactions (including dermatitis acneiform, pruritus, dry skin)

Other Adverse Reactions

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Patient Selection:

Storage requirements:

General:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.